Tysabri Clinical Trials Could Resume Before Product Re-Enters Market

Clinical trials for Biogen Idec/Elan's Tysabri (natalizumab) could resume before completion of discussions on whether the multiple sclerosis therapy should return to the market, Biogen Idec said during a July 26 earnings call